Grading Evolution and Contemporary Prognostic Biomarkers of Clinically Significant Prostate Cancer

SIMPLE SUMMARY: Prostate cancer treatment decisions are based on clinical stage and histological diagnosis, including Gleason grading assessed by a pathologist, in biopsies. Prior to staging and grading, serum or blood prostate-specific antigen (PSA) levels are measured and often trigger diagnostic...

Descripción completa

Detalles Bibliográficos
Autores principales: Sopyllo, Konrad, Erickson, Andrew M., Mirtti, Tuomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7914622/
https://www.ncbi.nlm.nih.gov/pubmed/33562508
http://dx.doi.org/10.3390/cancers13040628

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7914622/
https://www.ncbi.nlm.nih.gov/pubmed/33562508
http://dx.doi.org/10.3390/cancers13040628

Ejemplares similares